Skip to main content
SpringerLink
Log in

Belatacept als „standard of care“ für die Nierentransplantation?

Belatacept as standard of care for kidney transplantation?

  • Für Sie gelesen
  • Published:
Der Nephrologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Durrbach A, Pestana JM, Florman S et al (2016) Long-term outcomes in belatacept-treated vs. cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study. Am J Transplant. doi:10.1111/ajt.13830

    Google Scholar 

  2. Espinosa J, Herr F, Tharp G et al (2016) CD57(+) CD4 T cells underlie belatacept-resistant allograft rejection. Am J Transplant 16:1102–1112

    Article  CAS  PubMed  Google Scholar 

  3. Gupta G, Regmi A, Kumar D et al (2015) Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction. Am J Transplant 15:2726–2731

    Article  CAS  PubMed  Google Scholar 

  4. Lamb KE, Lodhi S, Meier-Kriesche HU (2011) Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 11:450–462

    Article  CAS  PubMed  Google Scholar 

  5. Le Meur Y, Aulagnon F, Bertrand D et al (2016) Effect of an early switch to belatacept among calcineurin inhibitor-intolerant graft recipients of kidneys from extended-criteria donors. Am J Transplant 16:2181–2186

    Article  CAS  PubMed  Google Scholar 

  6. Nickerson PW, Rush DN (2015) Begin at the beginning to prevent the end. J Am Soc Nephrol 26:1483–1485

    Article  PubMed  PubMed Central  Google Scholar 

  7. Pestana JO, Grinyo JM, Vanrenterghem Y et al (2012) Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 12:630–639

    Article  CAS  PubMed  Google Scholar 

  8. Rostaing L, Massari P, Garcia VD et al (2011) Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 6:430–439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rostaing L, Vincenti F, Grinyo J et al (2013) Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant 13:2875–2883

    Article  CAS  PubMed  Google Scholar 

  10. Vincenti F, Larsen CP, Alberu J et al (2012) Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 12:210–217

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrologie und Hypertensiologie, Universitätsklinikum Erlangen, Friedrich Alexander Universität Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Deutschland

    M. Wiesener

Authors
  1. M. Wiesener
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Wiesener.

Ethics declarations

Interessenkonflikt

M. Wiesener hat Honorare und Reise-Unterstützung für Kongresse von der Firnma BMS erhalten.

Additional information

Redaktion

T. Feldkamp, Kiel

J. Lutz, Mainz

L.T. Weber, Köln

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wiesener, M. Belatacept als „standard of care“ für die Nierentransplantation?. Nephrologe 11, 437–440 (2016). https://doi.org/10.1007/s11560-016-0096-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-016-0096-8

Search

Navigation